R M Marijnissen1, N Vogelzangs2, M E Mulder1, R H S van den Brink3, H C Comijs4, R C Oude Voshaar3. 1. Department of Old Age Psychiatry,ProPersona,Arnhem/Wolfheze,The Netherlands. 2. Department of Epidemiology,Cardiovascular Research Institute Maastricht (CARIM) & Maastricht Centre for Systems Biology (MaCSBio),Maastricht University,Maastricht,The Netherlands. 3. University Center of Psychiatry & Interdisciplinary Center for Psychopathology of Emotion Regulation,University Medical Center Groningen,University of Groningen,Groningen,The Netherlands. 4. Department Psychiatry,EMGO Institute for Health and Care Research VU University Medical Center/GGZinGeest,Amsterdam,The Netherlands.
Abstract
BACKGROUND: Depression is associated with the metabolic syndrome (MS). We examined whether metabolic dysregulation predicted the 2-year course of clinical depression. METHOD: A total of 285 older persons (⩾60 years) suffering from depressive disorder according to DSM-IV-TR criteria was followed up for 2 years. Severity of depression was assessed with the Inventory of Depressive Symptomatology (IDS) at 6-month intervals. Metabolic syndrome was defined according the National Cholesterol Education Programme (NCEP-ATP III). We applied logistic regression and linear mixed models adjusted for age, sex, years of education, smoking, alcohol use, physical activity, somatic co-morbidity, cognitive functioning and drug use (antidepressants, anti-inflammatory drugs) and severity of depression at baseline. RESULTS: MS predicted non-remission at 2 years (odds ratioper component = 1.26, 95% confidence interval 1.00-1.58), p = 0.047), which was driven by the waist circumference and HDL cholesterol. MS was not associated with IDS sum score. Subsequent analyses on its subscales, however, identified an association with the somatic symptom subscale score over time (interaction time × somatic subscale, p = 0.005), driven by higher waist circumference and elevated fasting glucose level. CONCLUSIONS: Metabolic dysregulation predicts a poor course of late-life depression. This finding supports the concept of 'metabolic depression', recently proposed on population-based findings of a protracted course of depressive symptoms in the presence of metabolic dysregulation. Our findings seem to be driven by abdominal obesity (as indicated by the waist circumference) and HDL cholesterol dysregulation.
BACKGROUND:Depression is associated with the metabolic syndrome (MS). We examined whether metabolic dysregulation predicted the 2-year course of clinical depression. METHOD: A total of 285 older persons (⩾60 years) suffering from depressive disorder according to DSM-IV-TR criteria was followed up for 2 years. Severity of depression was assessed with the Inventory of Depressive Symptomatology (IDS) at 6-month intervals. Metabolic syndrome was defined according the National Cholesterol Education Programme (NCEP-ATP III). We applied logistic regression and linear mixed models adjusted for age, sex, years of education, smoking, alcohol use, physical activity, somatic co-morbidity, cognitive functioning and drug use (antidepressants, anti-inflammatory drugs) and severity of depression at baseline. RESULTS: MS predicted non-remission at 2 years (odds ratioper component = 1.26, 95% confidence interval 1.00-1.58), p = 0.047), which was driven by the waist circumference and HDL cholesterol. MS was not associated with IDS sum score. Subsequent analyses on its subscales, however, identified an association with the somatic symptom subscale score over time (interaction time × somatic subscale, p = 0.005), driven by higher waist circumference and elevated fasting glucose level. CONCLUSIONS: Metabolic dysregulation predicts a poor course of late-life depression. This finding supports the concept of 'metabolic depression', recently proposed on population-based findings of a protracted course of depressive symptoms in the presence of metabolic dysregulation. Our findings seem to be driven by abdominal obesity (as indicated by the waist circumference) and HDL cholesterol dysregulation.
Authors: John S Mulvahill; Ginger E Nicol; David Dixon; Eric J Lenze; Jordan F Karp; Charles F Reynolds; Daniel M Blumberger; Benoit H Mulsant Journal: J Am Geriatr Soc Date: 2017-12 Impact factor: 5.562
Authors: J Fernandes de Souza Barbosa; C Dos Santos Gomes; J Vilton Costa; T Ahmed; M V Zunzunegui; C-L Curcio; F Gomez; R Oliveira Guerra Journal: J Nutr Health Aging Date: 2018 Impact factor: 4.075
Authors: Richard C Oude Voshaar; Ton D F Dhondt; Mario Fluiter; Paul Naarding; Sanne Wassink; Maureen M J Smeets; Loeki P R M Pelzers; Astrid Lugtenburg; Martine Veenstra; Radboud M Marijnissen; Gert-Jan Hendriks; Lia A Verlinde; Robert A Schoevers; Rob H S van den Brink Journal: BMC Psychiatry Date: 2019-06-17 Impact factor: 3.630
Authors: Sophia Frangou; Masoud Shirali; Mark J Adams; David M Howard; Jude Gibson; Lynsey S Hall; Blair H Smith; Sandosh Padmanabhan; Alison D Murray; David J Porteous; Chris S Haley; Ian J Deary; Toni-Kim Clarke; Andrew M McIntosh Journal: Exp Neurol Date: 2019-04-06 Impact factor: 5.330
Authors: K J E Kokkeler; R M Marijnissen; K J Wardenaar; D Rhebergen; R H S van den Brink; R C van der Mast; R C Oude Voshaar Journal: Psychol Med Date: 2020-07-03 Impact factor: 7.723